Details of the Drug

General Information of Drug (ID: DM49WQQ)

Drug Name

Reltecimod

Synonyms

UNII-U00J02UY29; 1447799-33-8; AB103; U00J02UY29; 1447799-33-8 (free); (S)-3-((S)-2-((S)-2-((S)-2-((S)-2-((S)-2-((S)-1-(D-alanyl-L-seryl)pyrrolidine-2-carboxamido)-4-(methylthio)butanamido)-4-methylpentanamido)-3-methylbutanamido)propanamido)-3-(4-hydroxyphenyl)propanamido)-4-(((R)-1-carboxyethyl)amino)-4-oxobutanoic acid; Reltecimod [INN]; Reltecimod [USAN]; Reltecimod (USAN/INN); Reltecimod [USAN:INN]; CHEMBL3989950; D11281; Q27290502; (5S,8S,11S,14S,17S,20S,23R)-5-((S)-1-((S)-2-((R)-2-Aminopropanamido)-3-hydroxypropanoyl)pyrrolidine-2-carboxamido)-20-(carboxymethyl)-17-(4-hydroxybenzyl)-8-isobutyl-11-isopropyl-14,23-dimethyl-6,9,12,15,18,21-hexaoxo-2-thia-7,10,13,16,19,22-hexaazatetracosan-24-oic acid; D-Alanine, D-alanyl-L-seryl-L-prolyl-L-methionyl-L-leucyl-L-valyl-L-alanyl-L-tyrosyl-L-alpha-aspartyl-; D-Alanyl-(t-cell-specific surface glycoprotein CD28-(8-15)- peptide)-D-alanine:D-alanyl-L-seryl-L-prolyl-L-methionyl-L-leucyl-L-valyl-L-alanyl-L-tyrosyl-L-alpha-aspartyl-D-alanine immunomodulator

Indication

Disease Entry	ICD 11	Status	REF
Necrotizing soft tissue infection	1B71	Phase 3	[1]
------------------------------------------------------------------------------------

Drug Type

Peptide

Structure

3D MOL is unavailable

2D MOL

Chemical Identifiers

Formula: C46H72N10O15S
Canonical SMILES: CC(C)CC(C(=O)NC(C(C)C)C(=O)NC(C)C(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(CC(=O)O)C(=O)NC(C)C(=O)O)NC(=O)C(CCSC)NC(=O)C2CCCN2C(=O)C(CO)NC(=O)C(C)N
InChI: 1S/C46H72N10O15S/c1-22(2)18-30(52-39(63)29(15-17-72-8)50-43(67)34-10-9-16-56(34)45(69)33(21-57)54-37(61)24(5)47)42(66)55-36(23(3)4)44(68)48-25(6)38(62)51-31(19-27-11-13-28(58)14-12-27)41(65)53-32(20-35(59)60)40(64)49-26(7)46(70)71/h11-14,22-26,29-34,36,57-58H,9-10,15-21,47H2,1-8H3,(H,48,68)(H,49,64)(H,50,67)(H,51,62)(H,52,63)(H,53,65)(H,54,61)(H,55,66)(H,59,60)(H,70,71)/t24-,25+,26-,29+,30+,31+,32+,33+,34+,36+/m1/s1
InChIKey: VRNHFZYMPDKTBS-WYUJEMNCSA-N

Cross-matching ID

PubChem CID: 71652162
CAS Number: 1447799-33-8
TTD ID: D9HYU8

References

1	ClinicalTrials.gov (NCT03403751) Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury. U.S. National Institutes of Health.